<\/p>\n
Hytrin<\/strong> je 1 \/ 2 \/ 5 mg Terazosin tablet<\/strong> from AbbVie — a long-acting selective alpha-1 adrenergic receptor antagonist (quinazoline)<\/strong>, p\u016fsob\u00ed na post-synaptic alpha-1 adrenergic receptors on arterial smooth muscle and on prostatic\/bladder-neck smooth muscle<\/strong>. Terazosin was introduced by Abbott (now AbbVie) in 1987 as Hytrin<\/strong> — developed as a longer-acting successor to prazosin, with a 12-hour half-life that permits once-daily dosing. Structurally a close quinazoline analogue of prazosin. Widely used in the 1990s and 2000s for benign prostatic hyperplasia (BPH) and as an add-on antihypertensive; partially displaced by the prostate-selective alpha-1A blockers (tamsulosin, silodosin) for BPH-only use, but retains a strong position where coexisting hypertension makes a non-selective alpha-blocker appropriate. Half-life 12 hours (once-daily dosing appropriate); onset 1-2 hours; peak 1-2 hours; symptomatic BPH benefit typically at 2-4 weeks. Primary indications: benign prostatic hyperplasia, resistant hypertension as add-on agent<\/strong>. Typick\u00e9 d\u00e1vkov\u00e1n\u00ed: Hypertenze:<\/strong> start 1 mg at bedtime (first-dose phenomenon risk), titrate every 1-2 weeks up to 5-20 mg\/day. The longer half-life vs prazosin makes once-daily dosing practical. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> ALLHAT stopped the doxazosin arm early for excess HF; terazosin is extrapolated to the same class concern. Reserve for fourth\/fifth-line use, especially where BPH coexists. V\u017edy pod\u00e1vejte prvn\u00ed d\u00e1vku p\u0159ed span\u00edm<\/strong> \u2014 fenom\u00e9n \u201cprvn\u00ed d\u00e1vky\u201d zp\u016fsobuje z\u00e1va\u017enou ortostatickou hypotenzi v po\u010d\u00e1te\u010dn\u00edch hodin\u00e1ch. Nen\u00ed prvn\u00ed volbou antihypertenziv (obavy z t\u0159\u00eddy ALLHAT) \u2014 vyhrazeno pro \u010dtvrtou\/p\u00e1tou linii, zejm\u00e9na tam, kde se vyskytuje BPH. U v\u011bt\u0161iny hypertonik\u016f modern\u00ed l\u00e9\u010dba za\u010d\u00edn\u00e1 ACE inhibitorem\/ARB, blok\u00e1torem kalciov\u00fdch kan\u00e1l\u016f, thiazidem a spironolaktonem, ne\u017e se p\u0159istoup\u00ed k alfa-blok\u00e1toru nebo centr\u00e1ln\u011b p\u016fsob\u00edc\u00edmu \u010dinidlu.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Hytrin is an oral 1 \/ 2 \/ 5 mg Terazosin tablet from AbbVie, supplied in 30-180 tablets. Terazosin was introduced by Abbott (now AbbVie) in 1987 as Hytrin<\/strong> — developed as a longer-acting successor to prazosin, with a 12-hour half-life that permits once-daily dosing. Structurally a close quinazoline analogue of prazosin. Widely used in the 1990s and 2000s for benign prostatic hyperplasia (BPH) and as an add-on antihypertensive; partially displaced by the prostate-selective alpha-1A blockers (tamsulosin, silodosin) for BPH-only use, but retains a strong position where coexisting hypertension makes a non-selective alpha-blocker appropriate.<\/p>\n Terazosin acts on post-synaptic alpha-1 adrenergic receptors on arterial smooth muscle and on prostatic\/bladder-neck smooth muscle<\/strong>. N\u00e1sledn\u00e9 \u00fa\u010dinky:<\/p>\n Kl\u00ed\u010dov\u00e9 d\u016fkazy z klinick\u00fdch studi\u00ed:<\/strong> HYTRIN Community Assessment Trial (HYCAT, 1996)<\/strong> — terazosin improved IPSS by 37% in 2,084 men with symptomatic BPH over 1 year. VA Cooperative BPH Trial (Lepor, NEJM 1996)<\/strong> — terazosin + finasteride no better than terazosin alone in men with smaller prostates, foreshadowing the MTOPS finding that combination therapy helps larger prostates. ALLHAT doxazosinov\u00e1 v\u011btev (2000)<\/strong> — class-level HF signal.<\/p>\n Z\u00e1kladn\u00ed d\u00e1vka:<\/strong> Hypertenze:<\/strong> start 1 mg at bedtime (first-dose phenomenon risk), titrate every 1-2 weeks up to 5-20 mg\/day. The longer half-life vs prazosin makes once-daily dosing practical. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> ALLHAT stopped the doxazosin arm early for excess HF; terazosin is extrapolated to the same class concern. Reserve for fourth\/fifth-line use, especially where BPH coexists.<\/p>\n Dal\u0161\u00ed indikace:<\/strong> 1 mg at bedtime initially, titrating by 1 mg every 3-5 days to clinical effect. Typical effective dose 2-10 mg at bedtime; some patients require 15-20 mg. Evidence base: Raskind and Peskind RCTs (2003-2013) showed significant reduction in nightmare frequency and improvement in sleep architecture, though the larger 2018 PACT trial was negative \u2014 enthusiasm tempered but use remains common when CBT-I and trauma-focused psychotherapy are inadequate.<\/strong> start 1 mg at bedtime, titrate to 5-10 mg once daily over 2-4 weeks. Dose at bedtime indefinitely to minimise orthostatic effects. Symptom benefit typically clear by 4-6 weeks; if inadequate, switch to or add a prostate-selective alpha-1A blocker (tamsulosin) or a 5-alpha-reductase inhibitor (finasteride) for larger prostates (>40 g).<\/p>\n Pod\u00e1v\u00e1n\u00ed:<\/strong> take once daily at bedtime. Food does not significantly affect absorption.<\/p>\n Monitorovac\u00ed pl\u00e1n:<\/strong><\/p>\n Ukon\u010den\u00ed l\u00e9\u010dby:<\/strong> \u017e\u00e1dn\u00fd rebound syndrom. Alfa-blok\u00e1tory lze vysadit, ale o\u010dek\u00e1vejte ur\u010dit\u00fd vzestup TK, pokud v\u00fdznamn\u011b p\u0159isp\u00edvaly k jeho kontrole. P\u0159i op\u011btovn\u00e9m nasazen\u00ed po p\u0159eru\u0161en\u00ed >1 t\u00fddne za\u010dn\u011bte od po\u010d\u00e1te\u010dn\u00ed d\u00e1vky (ne od p\u0159edchoz\u00ed udr\u017eovac\u00ed d\u00e1vky) \u2014 fenom\u00e9n prvn\u00ed d\u00e1vky se vrac\u00ed.<\/p>\n \u010cast\u00e9 (>1 %):<\/strong><\/p>\n Nep\u0159\u00edli\u0161 \u010dast\u00e9, ale klinicky v\u00fdznamn\u00e9:<\/strong><\/p>\n T\u011bhotenstv\u00ed:<\/strong> vyvarujte se \u2014 omezen\u00e9 \u00fadaje o t\u011bhotenstv\u00ed u alfa-blok\u00e1tor\u016f. P\u0159i hypertenzi v t\u011bhotenstv\u00ed p\u0159ejd\u011bte na methyldopu, labetalol nebo nifedipin.<\/p>\n Kojen\u00ed:<\/strong> omezen\u00e9 \u00fadaje; pou\u017e\u00edvejte s opatrnost\u00ed. Pokud mo\u017eno p\u0159ejd\u011bte na l\u00e9k s lep\u0161\u00edmi \u00fadaji o kojen\u00ed (labetalol, nifedipin, enalapril).<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Hytrin?<\/h2>\n
How Terazosin Works<\/h2>\n
\n
Schv\u00e1len\u00e9 a v\u011bdecky podlo\u017een\u00e9 indikace<\/h2>\n
\n
Hytrin Dosage<\/h2>\n
\n
Practical Considerations for Hytrin<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n
\n
\n
Kontraindikace<\/h2>\n
\n
Interakce s l\u00e9\u010divy<\/h2>\n
\n
Where Hytrin Fits in the Antihypertensive Hierarchy<\/h2>\n